ODG
COGT icon

O'Dell Group’s Cogent Biosciences COGT Stock Holding History

O'Dell Group’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-35
Closed -$206 – 163
2023
Q4 		$206 Buy
+35
New +$268 ﹤0.01% 489
2023
Q3 		– Sell
-35
Closed -$415 – 147
2023
Q2 		$415 Buy
+35
New +$402 ﹤0.01% 481

Other funds holding COGT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

O'Dell Group's COGT Position: Q1 2024 in Review

O'Dell Group sold out of Cogent Biosciences (COGT) in Q1 2024, closing a stake of 35 shares — an estimated $206 sold.

O'Dell Group first reported a position in COGT in Q2 2023 and held it in 2 quarters. The position peaked at $415 in Q2 2023. 146 funds tracked by Wall St. Rank hold COGT as of Q1 2024.

  • O'Dell Group reported no remaining Cogent Biosciences position as of Q1 2024 after selling out during the quarter.
  • O'Dell Group sold 35 Cogent Biosciences shares in Q1 2024, an estimated $206.
  • O'Dell Group first reported a position in Cogent Biosciences in Q2 2023 and held it in 2 quarters.
  • O'Dell Group's Cogent Biosciences position peaked at $415 in Q2 2023.
  • 146 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2024.

Based on O'Dell Group's 13F filing for Q1 2024, filed 7 May 2024.